Universal Genetic Testing Is Far From a Reality in Patients With Ovarian Cancer
A new review points to low rates of genetic testing in patients with ovarian cancer.
Ovarian Cancer
Injection May Illuminate Hard-to-Spot Ovarian Cancer Lesions for Surgical Resection
One-third of patients had an additional lesion removed with use of pafolacianine sodium.
Mirvetuximab Soravtansine Plus Bevacizumab Looks Promising in Platinum-Agnostic Ovarian Cancer
The combination produced durable responses in patients with high folate receptor alpha expression.
Secondary Cytoreduction Improves Progression-Free Survival in Platinum-Sensitive, Relapsed Ovarian Cancer
The median progression-free survival was nearly 6 months longer in patients who underwent surgery.
Lack of Standardized Screening Linked to Increased Incidence of Many HPV-Related Cancers
For HPV-related cancers without standardized screening, incidence rates increased between 2001 and 2017.
Maintenance Therapy With Olaparib Improves Survival in Relapsed Ovarian Cancer
Investigators performed a final analysis of SOLO2 to investigate the effect of olaparib on overall survival in patients with ovarian cancer and a BRCA1/2 mutation.
PARP Inhibitor Maintenance Improves PFS in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer
Maintenance with a PARP inhibitor benefited all subsets of patients
Study Reports Improved Outcomes With Olaparib Maintenance in Ovarian Cancer
A team of investigators conducted a double-blind, placebo-controlled, phase 3 trial to assess outcomes following olaparib treatment in patients with BRCA 1/2-mutated, relapsed ovarian cancer.
Most Patients With Breast, Ovarian Cancer Do Not Undergo Genetic Testing
The number of genes tested for ovarian and breast cancer has grown, but most patients do not undergo testing, and variant-of-unknown-significance results are common, especially among minority populations.
FDA-Approved Ovarian Cancer Treatments
FDA-Approved treatment options for individuals with ovarian cancer including dosing.
- Loading...
Loading...
Loading... 
Loading...